[EN] A PROCESS FOR THE PREPARATION OF RIVAROXABAN BASED ON THE USE OF (S)-EPICHLOROHYDRIN<br/>[FR] PROCÉDÉ DE PRÉPARATION DE RIVAROXABAN FONDÉ SUR L'UTILISATION DE (S)-ÉPICHLOROHYDRINE
申请人:ZENTIVA KS
公开号:WO2013120465A1
公开(公告)日:2013-08-22
The invention relates to the stereoisomers of 4-4-[(S/R)-5-[(((aryl)methylene)- amino)methyl]-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-ones described by the chemical formulae (S)-(9) and (R)-(9). The optical isomer of compound (9) with the (S)- configuration is industrially applicable for the manufacture of the antithrombotic drug rivaroxaban (1). The new preparation process of rivaroxaban comprises a reaction of (S)-1- chloro-3-(((aryl)methylene)amino)propan-2-ols (S)-(14) with alkyl 4-(3-oxomorpholine-4- yl)phenylcarbamates (15) providing the key intermediate (S)-(9), which is further subjected to hydrolytic deprotection and subsequent acylation, producing rivaroxaban. The commercially available (S)-epichlorohydrin has been conveniently used as the chiral building block for the production of the key intermediate.
该发明涉及4-4-[(S/R)-5-[(((芳基)亚甲基)氨基)甲基]-2-氧代-1,3-噁唑烷-3-基]苯基}吗啡啶-3-酮的立体异构体,化学式分别为(S)-(9)和(R)-(9)。化合物(9)的光学异构体,具有(S)-构型,可用于工业制造抗凝血药利伐沙班(1)。利伐沙班的新制备过程包括(S)-1-氯-3-(((芳基)亚甲基)氨基)丙烷-2-醇(S)-(14)与烷基4-(3-氧代吗啡啶-4-基)苯基氨甲酸酯(15)发生反应,得到关键中间体(S)-(9),随后经水解去保护和酰化反应,制备利伐沙班。商业上可获得的(S)-环氧氯丙烷已方便地用作生产关键中间体的手性构建块。